2023-507788-20-00已完成1 期
A phase 1, open-label, cross-over study in healthy volunteers to assess the pharmacokinetic profile of Prazosin and Cyproheptadine following single dose oral administration of KT110 tablet and following administration of Alpress and Periactine marketed tablets
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Lucas BIELA
Scientific
Kinnov Therapeutics
研究点 (1)
Loading locations...
相似试验
暂停
1 期
Drug interaction assessment of GSK3882347 in healthy participants aged 18 to 65 yearsHealthy volunteer drug interaction studyISRCTN16147016GlaxoSmithKline (United Kingdom)30
未知
1 期
A Phase 1, Food Effect Study of TAK-385 Final FormulatioJPRN-jRCT2080223218TAKEDA PHARMACEUTICAL COMPANY LTD.35
进行中（未招募）
1 期
A study to assess the food effect and how fast JNJ-53718678 reaches the blood stream of healthy adult subjects after being dosed with 250-mg as an oral solid concept compared with suspension; and the effect of storage conditions on how long the drug stays and acts in the body after administration of JNJ-53718678Respiratory Syncytial VirusMedDRA version: 20.0Level: HLTClassification code 10038717Term: Respiratory syncytial viral infectionsSystem Organ Class: 100000004862EUCTR2020-000369-18-BEJanssen Sciences Ireland Unlimited Company (UC)84
进行中（未招募）
1 期
A Study to Evaluate the Relative Bioavailability of Tezacaftor/Ivacaftor GranulesMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-000689-40-Outside-EU/EEAVertex Pharmaceuticals Incorporated16
未知
1 期
A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg TabletsJPRN-jRCT2080222761TAKEDA PHARMACEUTICAL COMPANY LTD.24